Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Matrix metalloproteinase 12 (MMP-12), also known as macrophage metalloelastase, is a zinc-dependent endopeptidase in the matrix metalloproteinase family, primarily secreted by macrophages[1][2]. MMP-12 plays a crucial role in the degradation of extracellular matrix proteins, especially elastin, during physiological processes such as tissue remodeling, embryonic development, and reproduction, and in pathological conditions including atherosclerosis, aneurysm, emphysema, arthritis, and tumor metastasis[1][2][3]. High MMP-12 expression is associated with advanced atherosclerotic plaques, plaque vulnerability, and the promotion of apoptosis in plaque macrophages, contributing to disease progression and instability[3]. It is a validated therapeutic target for several diseases with tissue remodeling and inflammatory components, but clinical targeting is limited by broad MMP inhibitor toxicity[2][3].
Inhibition of proteolytic (elastolytic) activity to prevent extracellular matrix degradation and tissue remodeling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Matrix metalloproteinase 12 (MMP-12).